CELYAD | Two allogeneic platforms to speed up a CAR
Celyad is leveraging its expertise in CAR-T development to progress both allogeneic and autologous therapies, with the cornerstone approach of using NKG2D receptor to target tumour cells. In our view, while company’s autologous franchise, including CYAD-01 and CYAD-02 programmes, could support the potential of NKG2D-CAR and provide clinical catalysts in the near-term, on the long run allogeneic franchise could be a major value-driver for the company.Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.